Kennedy Ferruggia, Associate Editor

Adults with underlying medical conditions, resulting in an increased risk of respiratory syncytial virus disease are more likely to be cost-effective than general age-based strategies.

Vitamin D supplementation improved total cholesterol levels, systolic blood pressure, diastolic blood pressure, and all glycemic parameters.

If approved, delgocitinib cream would be the first US treatment indicated for moderate to severe chronic hand eczema.

Ponsegromab displayed significant and robust increases in body weight at the completion of the study for all doses.

Dermatomal reactions could occur following recombinant zoster vaccine to treat shingles.

Results displayed a non-inferior immune response of the co-administered vaccines, compared to administration in individual visits.

There is a need for continued research and awareness in the diagnosis and management of alopecia in diverse populations.

Not only do diverse clinical cohorts improve the strength of the data, but it improves public trust in clinicians and the medical system as a whole.

Immediate-early 62 enclosed inside small extracellular vesicles can transport from the site of infection, causing it to penetrate cells and shut down their antiviral response.

An overview of the potential treatment strategies for patients were presented at the 2024 World Conference on Lung Cancer.

Chronic fatigue is a related symptom with inflammatory bowel disease (IBD).

An overview of the latest developments in targeting DLL3 in lung neuroendocrine tumors were presented at the 2024 World Conference on Lung Cancer.

NS-050/NCNP-03 is being developed to aid individuals with confirmed gene mutations that are treatable with exon 50 skipping therapy.

Individuals with a history of shingles was significantly and independently connected with a 20% higher risk of for subjective cognitive decline.

RSV vaccination was 75% effective in preventing RSV-associated hospitalizations among adults aged 60 years and older.

There is no significant impact on maternal or infant health outcomes when taking an additional iron supplement

OBX-115 could offer further treatment options for individuals with advanced or metastatic melanoma by enhancing persistence, antitumor activity, and clinical safety of TIL cell therapy.

Shared clinical decision-making presented drawbacks, resulting in age-based recommendations for adults aged 75 years and older and risk-based recommendations for individuals aged 60-74 years.

The findings further the understanding of respiratory virus immune evasion mechanisms and uncover how RSV-NS1 can target therapeutic intervention

"Risk Less. Do More." plans to partner with national, state, and local organizations to provide resources to families and communities on how to protect themselves from RSV, influenza, and COVID-19.

Mirdametinib is an oral, allosteric small molecule MEK inhibitor to treat pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

Eight areas of improvement were developed as part of national initiative with stakeholder involvement.

Pegcetacoplan is a targeted C3 therapy that is intended to regulate excessive activation of the complement cascade.

Pediatric patients weighing 20 kg to <50 kg should take 20 mg of apremilast twice daily and children weighing at least 50 kg should take 30 mg twice daily.

Building trust between techs and patients makes administering vaccines easier and increase immunizers’ confidence.

Pharmacists can help caregivers by recommending a healthy balanced diet containing high vitamin D intake and supplementation when needed.

Researchers assess the safety, tolerability, and immunogenicity of a single combination dose to evaluate its immunogenicity against SARS-CoV-2 and influenza.

Individuals with chronic conditions like asthma, diabetes, and chronic obstructive pulmonary disease face an increased risk of developing RSV.

The breakthrough therapy designation was granted based on ongoing data from the ARTEMIS-001 phase 1 open-label, multi-center trial.

Fam-trastuzumab deruxtecan-nxki has received 4 breakthrough therapy designations, including the latest approval.